Standard Chemical & Pharmaceutical Co. Ltd.(TW:1720)
NT$55.00-0.10 (-0.54%)
TW:1720
Standard Chemical & Pharmaceutical Co. Ltd. financials statements
NT$55.00
At close:-0.10 (-0.54%)
Standard Chemical & Pharmaceutical Co. Ltd. (1720) Ratios
Standard Chemical & Pharmaceutical Co. Ltd. Ratios
TW:1720's free cash flow for Q2 2026 was NT$13.35M. For the 2026 fiscal year, TW:1720's free cash flow was decreased by NT$-126.63M and operating cash flow was NT$139.97M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.53 | 3.01 | 2.29 | 1.94 | 2.13 |
| Quick Ratio | 1.80 | 1.98 | 1.60 | 1.46 | 1.68 |
| Cash Ratio | 0.85 | 0.92 | 0.86 | 0.78 | 0.94 |
| Solvency Ratio | 0.54 | 0.58 | 0.39 | 0.41 | 0.28 |
| Operating Cash Flow Ratio | 0.86 | 1.02 | 0.56 | 0.43 | 0.30 |
| Short-Term Operating Cash Flow Coverage | 2.07 | 3.20 | 1.56 | 0.68 | 0.50 |
| Net Current Asset Value | NT$ 2.95B | NT$ 2.80B | NT$ 2.37B | NT$ 2.06B | NT$ 2.48B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.08 | 0.12 | 0.20 | 0.19 |
| Debt-to-Equity Ratio | 0.18 | 0.16 | 0.25 | 0.47 | 0.45 |
| Debt-to-Capital Ratio | 0.16 | 0.13 | 0.20 | 0.32 | 0.31 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.03 | 0.04 | 0.04 | 0.01 |
| Financial Leverage Ratio | 1.93 | 1.89 | 2.11 | 2.31 | 2.33 |
| Debt Service Coverage Ratio | 1.69 | 3.17 | 1.50 | 0.77 | 0.64 |
| Interest Coverage Ratio | 161.32 | 92.66 | 48.83 | 76.51 | 140.96 |
| Debt to Market Cap | 0.07 | 0.07 | 0.10 | 0.20 | 0.24 |
| Interest Debt Per Share | 4.70 | 5.24 | 7.57 | 12.68 | 11.06 |
| Net Debt to EBITDA | -0.39 | -0.29 | -0.44 | -0.01 | -0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.42% | 44.02% | 43.68% | 42.51% | 44.91% |
| EBIT Margin | 19.40% | 24.36% | 20.19% | 24.25% | 22.18% |
| EBITDA Margin | 25.58% | 30.32% | 25.76% | 28.30% | 27.11% |
| Operating Profit Margin | 19.40% | 20.57% | 20.19% | 24.55% | 22.20% |
| Pretax Profit Margin | 21.56% | 23.97% | 23.04% | 23.92% | 22.02% |
| Net Profit Margin | 13.21% | 12.97% | 13.38% | 19.72% | 15.35% |
| Continuous Operations Profit Margin | 17.88% | 19.06% | 18.56% | 18.67% | 18.18% |
| Net Income Per EBT | 61.28% | 54.11% | 58.06% | 82.41% | 69.71% |
| EBT Per EBIT | 111.09% | 116.55% | 114.16% | 97.45% | 99.20% |
| Return on Assets (ROA) | 7.86% | 7.88% | 7.46% | 10.52% | 6.99% |
| Return on Equity (ROE) | 15.15% | 14.91% | 15.76% | 24.27% | 16.28% |
| Return on Capital Employed (ROCE) | 14.14% | 14.68% | 14.28% | 17.76% | 13.83% |
| Return on Invested Capital (ROIC) | 10.70% | 11.03% | 10.46% | 11.94% | 9.30% |
| Return on Tangible Assets | 8.01% | 8.03% | 7.61% | 10.74% | 7.16% |
| Earnings Yield | 7.16% | 8.76% | 7.80% | 11.55% | 10.09% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.12 | 5.07 | 4.40 | 3.95 | 3.09 |
| Payables Turnover | 10.14 | 15.68 | 13.06 | 14.72 | 7.87 |
| Inventory Turnover | 2.62 | 2.21 | 2.18 | 2.43 | 2.08 |
| Fixed Asset Turnover | 1.50 | 1.49 | 1.43 | 1.42 | 1.49 |
| Asset Turnover | 0.60 | 0.61 | 0.56 | 0.53 | 0.46 |
| Working Capital Turnover Ratio | 2.11 | 2.13 | 2.17 | 2.03 | 1.83 |
| Cash Conversion Cycle | 174.46 | 213.96 | 222.75 | 217.95 | 246.95 |
| Days of Sales Outstanding | 71.25 | 72.01 | 82.97 | 92.30 | 118.13 |
| Days of Inventory Outstanding | 139.22 | 165.22 | 167.73 | 150.45 | 175.22 |
| Days of Payables Outstanding | 36.00 | 23.27 | 27.95 | 24.80 | 46.40 |
| Operating Cycle | 210.46 | 237.23 | 250.70 | 242.75 | 293.35 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 7.71 | 9.49 | 7.48 | 6.87 | 4.63 |
| Free Cash Flow Per Share | 5.69 | 6.13 | 3.98 | 0.17 | 3.41 |
| Dividend Paid and CapEx Coverage Ratio | 1.88 | 1.57 | 1.25 | 0.75 | 1.53 |
| Capital Expenditure Coverage Ratio | 3.81 | 2.83 | 2.14 | 1.03 | 3.80 |
| Operating Cash Flow Coverage Ratio | 1.65 | 1.84 | 1.01 | 0.55 | 0.42 |
| Operating Cash Flow to Sales Ratio | 0.27 | 0.25 | 0.21 | 0.21 | 0.18 |
| Free Cash Flow Yield | 10.62% | 10.89% | 6.64% | 0.30% | 8.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.32 | 11.39 | 12.83 | 8.65 | 9.89 |
| Price-to-Sales (P/S) Ratio | 1.84 | 1.48 | 1.72 | 1.71 | 1.52 |
| Price-to-Book (P/B) Ratio | 2.12 | 1.70 | 2.02 | 2.10 | 1.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.41 | 9.18 | 15.07 | 329.82 | 11.49 |
| Price-to-Operating Cash Flow Ratio | 6.95 | 5.93 | 8.01 | 8.14 | 8.47 |
| Price-to-Earnings Growth (PEG) Ratio | 2.04 | 1.97 | -0.46 | 0.14 | 0.28 |
| Enterprise Value Multiple | 6.82 | 4.59 | 6.22 | 6.03 | 5.13 |
| Enterprise Value | 12.25B | 9.46B | 10.00B | 9.98B | 6.41B |
| EV to EBITDA | 6.82 | 4.59 | 6.22 | 6.03 | 5.13 |
| EV to Sales | 1.74 | 1.39 | 1.60 | 1.71 | 1.39 |
| EV to Free Cash Flow | 8.90 | 8.63 | 14.07 | 329.44 | 10.52 |
| EV to Operating Cash Flow | 6.57 | 5.58 | 7.48 | 8.13 | 7.75 |
| Tangible Book Value Per Share | 37.53 | 49.07 | 44.32 | 40.35 | 36.80 |
| Shareholders’ Equity Per Share | 25.32 | 33.05 | 29.64 | 26.60 | 24.30 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.20 | 0.19 | 0.18 | 0.17 |
| Revenue Per Share | 29.03 | 37.99 | 34.90 | 32.74 | 25.76 |
| Net Income Per Share | 3.83 | 4.93 | 4.67 | 6.46 | 3.95 |
| Tax Burden | 0.61 | 0.54 | 0.58 | 0.82 | 0.70 |
| Interest Burden | 1.11 | 0.98 | 1.14 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 |
| SG&A to Revenue | 0.18 | 0.19 | 0.19 | 0.19 | 0.21 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.01 | 1.04 | 1.60 | 1.51 | 0.82 |
Currency in TWD
